139 related articles for article (PubMed ID: 33794728)
41. Post PCI severe gastrointestinal bleeding in the setting of idiopathic thrombocytopenic purpura: a treatment dilemma.
Ghafoor H; Sharma NK; Alampoondi Venkataramanan SV; Hadley M
BMJ Case Rep; 2021 Jun; 14(6):. PubMed ID: 34162622
[TBL] [Abstract][Full Text] [Related]
42. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
Ten Berg JM; de Veer A; Oldgren J; Steg PG; Zateyshchikov DA; Jansky P; Seung KB; Hohnloser SH; Lip GYH; Nordaby M; Kleine E; Bhatt DL; Cannon CP;
JACC Cardiovasc Interv; 2019 Dec; 12(23):2331-2341. PubMed ID: 31806214
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of single vs dual antiplatelet therapy in patients on anticoagulation undergoing percutaneous coronary intervention: A systematic review and meta-analysis.
Atti V; Turagam MK; Garg J; Velagapudi P; Patel NJ; Basir MB; Mujer MT; Rayamajhi S; Abela GS; Koerber S; Gopinnathanair R; Lakkireddy D
J Cardiovasc Electrophysiol; 2019 Nov; 30(11):2460-2472. PubMed ID: 31432607
[TBL] [Abstract][Full Text] [Related]
44. Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
Mishra A; Singh M; Acker WW; Kamboj S; Sporn D; Stapleton D; Kaluski E
J Cardiovasc Pharmacol; 2019 Aug; 74(2):82-90. PubMed ID: 31306367
[TBL] [Abstract][Full Text] [Related]
45. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients).
Baber U; Li SX; Pinnelas R; Pocock SJ; Krucoff MW; Ariti C; Gibson CM; Steg PG; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Iakovou I; Dangas G; Aquino MB; Sartori S; Chieffo A; Moliterno DJ; Colombo A; Mehran R
Circ Cardiovasc Interv; 2018 Mar; 11(3):e006144. PubMed ID: 29870385
[TBL] [Abstract][Full Text] [Related]
46. Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
Berry NC; Mauri L; Steg PG; Bhatt DL; Hohnloser SH; Nordaby M; Miede C; Kimura T; Lip GYH; Oldgren J; Ten Berg JM; Cannon CP
Circ Cardiovasc Interv; 2020 Apr; 13(4):e008349. PubMed ID: 32252548
[TBL] [Abstract][Full Text] [Related]
47. Dual versus triple therapy in patients on oral anticoagulants and undergoing coronary stent implantation: A systematic review and meta-analysis.
Fortuni F; Ferlini M; Leonardi S; Angelini F; Crimi G; Somaschini A; Cornara S; Potenza A; De Servi S; Oltrona Visconti L; De Ferrari GM
Int J Cardiol; 2018 Dec; 273():80-87. PubMed ID: 30115419
[TBL] [Abstract][Full Text] [Related]
48. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
[TBL] [Abstract][Full Text] [Related]
49. Impact of dual antiplatelet therapy duration on 1-year clinical outcomes in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the real-world OPT-CAD study.
Li J; Li Y; Qiu M; Li Z; Yang J; Wang X; Bao D; Wang X; Han Y
Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():579-586. PubMed ID: 31872515
[TBL] [Abstract][Full Text] [Related]
50. Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using PPI co-therapy.
Casado Arroyo R; Polo-Tomas M; Roncalés MP; Scheiman J; Lanas A
Heart; 2012 May; 98(9):718-23. PubMed ID: 22523056
[TBL] [Abstract][Full Text] [Related]
51. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
[TBL] [Abstract][Full Text] [Related]
52. Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding.
Ray WA; Chung CP; Murray KT; Smalley WE; Daugherty JR; Dupont WD; Stein CM
JAMA; 2018 Dec; 320(21):2221-2230. PubMed ID: 30512099
[TBL] [Abstract][Full Text] [Related]
53. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients.
Galli M; Andreotti F; Porto I; Crea F
Europace; 2020 Apr; 22(4):538-546. PubMed ID: 31942971
[TBL] [Abstract][Full Text] [Related]
54. Reduction in postpercutaneous coronary intervention angina in addition to gastrointestinal events in patients on combined proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis.
Khan MY; Siddiqui WJ; Alvarez C; Aggarwal S; Hasni SF; Ahmad A; Eisen H
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):847-853. PubMed ID: 29596078
[TBL] [Abstract][Full Text] [Related]
55. A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study.
Chen Y; Yin T; Xi S; Zhang S; Yan H; Tang Y; Qian J; Chen J; Su X; Du Z; Wang L; Qin Q; Gao C; Zheng Y; Zhao X; Cheng X; Li Z; Zhang W; Chen H; Wang J; Yang Z; Li H; Liu H; Zhou X; Qu B; Xiang D; Guo Y; Wang L; Nie S; Fu G; Yang M; Cai S
Catheter Cardiovasc Interv; 2019 Jun; 93(7):1194-1204. PubMed ID: 31112635
[TBL] [Abstract][Full Text] [Related]
56. Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy.
Sra S; Tan MK; Mehta SR; Fisher HN; Déry JP; Welsh RC; Eisenberg MJ; Overgaard CB; Rose BF; Siega AJ; Cheema AN; Wong BY; Henderson MA; Lutchmedial S; Lavi S; Goodman SG; Yan AT;
Am Heart J; 2016 Oct; 180():82-9. PubMed ID: 27659886
[TBL] [Abstract][Full Text] [Related]
57. The Bleeding Risk in Antithrombotic Therapies: A Narrative Review.
Alatri A; Mazzolai L
Curr Vasc Pharmacol; 2020; 18(3):237-248. PubMed ID: 30747072
[TBL] [Abstract][Full Text] [Related]
58. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.
Kim HS; Kang J; Hwang D; Han JK; Yang HM; Kang HJ; Koo BK; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Park KW;
Lancet; 2020 Oct; 396(10257):1079-1089. PubMed ID: 32882163
[TBL] [Abstract][Full Text] [Related]
59. Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
Choi HI; Ahn JM; Kang SH; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ
JACC Cardiovasc Interv; 2017 Jun; 10(11):1075-1085. PubMed ID: 28527773
[TBL] [Abstract][Full Text] [Related]
60. Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.
Xanthopoulou I; Dragona VM; Davlouros P; Tsioufis C; Iliodromitis E; Alexopoulos D;
Cardiovasc Drugs Ther; 2018 Apr; 32(2):191-196. PubMed ID: 29679301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
